NEOGENOMICS INC (NEO) Stock Fundamental Analysis

NASDAQ:NEO • US64049M2098

9.65 USD
-0.32 (-3.21%)
At close: Feb 24, 2026
9.8687 USD
+0.22 (+2.27%)
After Hours: 2/24/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

NEO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. NEO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEO is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • NEO had positive earnings in the past year.
  • NEO had a positive operating cash flow in the past year.
  • NEO had negative earnings in each of the past 5 years.
  • In multiple years NEO reported negative operating cash flow during the last 5 years.
NEO Yearly Net Income VS EBIT VS OCF VS FCFNEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • NEO has a worse Return On Assets (-7.94%) than 70.30% of its industry peers.
  • Looking at the Return On Equity, with a value of -12.91%, NEO is doing worse than 61.39% of the companies in the same industry.
Industry RankSector Rank
ROA -7.94%
ROE -12.91%
ROIC N/A
ROA(3y)-5.99%
ROA(5y)-5.34%
ROE(3y)-10.33%
ROE(5y)-9.24%
ROIC(3y)N/A
ROIC(5y)N/A
NEO Yearly ROA, ROE, ROICNEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

1.3 Margins

  • With a decent Gross Margin value of 43.21%, NEO is doing good in the industry, outperforming 72.28% of the companies in the same industry.
  • NEO's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.44%
GM growth 5Y0.65%
NEO Yearly Profit, Operating, Gross MarginsNEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NEO has been increased compared to 1 year ago.
  • Compared to 5 years ago, NEO has more shares outstanding
  • NEO has a better debt/assets ratio than last year.
NEO Yearly Shares OutstandingNEO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NEO Yearly Total Debt VS Total AssetsNEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • NEO has an Altman-Z score of 1.56. This is a bad value and indicates that NEO is not financially healthy and even has some risk of bankruptcy.
  • NEO has a Altman-Z score (1.56) which is comparable to the rest of the industry.
  • NEO has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
  • NEO has a better Debt to Equity ratio (0.41) than 65.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 1.56
ROIC/WACCN/A
WACC6.96%
NEO Yearly LT Debt VS Equity VS FCFNEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • NEO has a Current Ratio of 4.26. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 4.26, NEO belongs to the best of the industry, outperforming 91.09% of the companies in the same industry.
  • NEO has a Quick Ratio of 3.94. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
  • NEO has a Quick ratio of 3.94. This is amongst the best in the industry. NEO outperforms 90.10% of its industry peers.
Industry RankSector Rank
Current Ratio 4.26
Quick Ratio 3.94
NEO Yearly Current Assets VS Current LiabilitesNEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.00% over the past year.
  • NEO shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -3.04% yearly.
  • NEO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.11%.
  • The Revenue has been growing by 10.35% on average over the past years. This is quite good.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5Y-3.04%
EPS Q2Q%50%
Revenue 1Y (TTM)10.11%
Revenue growth 3Y12.58%
Revenue growth 5Y10.35%
Sales Q2Q%10.56%

3.2 Future

  • NEO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.25% yearly.
  • Based on estimates for the next years, NEO will show a quite strong growth in Revenue. The Revenue will grow by 9.72% on average per year.
EPS Next Y35.15%
EPS Next 2Y72.06%
EPS Next 3Y62.52%
EPS Next 5Y49.25%
Revenue Next Year9.75%
Revenue Next 2Y9.5%
Revenue Next 3Y9.84%
Revenue Next 5Y9.72%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NEO Yearly Revenue VS EstimatesNEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
NEO Yearly EPS VS EstimatesNEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • NEO is valuated quite expensively with a Price/Earnings ratio of 80.42.
  • NEO's Price/Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Earnings ratio is at 26.98. NEO is valued rather expensively when compared to this.
  • Based on the Price/Forward Earnings ratio of 59.50, the valuation of NEO can be described as expensive.
  • The rest of the industry has a similar Price/Forward Earnings ratio as NEO.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.01, NEO is valued quite expensively.
Industry RankSector Rank
PE 80.42
Fwd PE 59.5
NEO Price Earnings VS Forward Price EarningsNEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEO Per share dataNEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates NEO does not grow enough to justify the current Price/Earnings ratio.
  • NEO's earnings are expected to grow with 62.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.29
PEG (5Y)N/A
EPS Next 2Y72.06%
EPS Next 3Y62.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NEO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEOGENOMICS INC

NASDAQ:NEO (2/24/2026, 8:00:01 PM)

After market: 9.8687 +0.22 (+2.27%)

9.65

-0.32 (-3.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-17
Earnings (Next)04-27
Inst Owners102.56%
Inst Owner Change0.27%
Ins Owners1.14%
Ins Owner Change0.37%
Market Cap1.25B
Revenue(TTM)727.33M
Net Income(TTM)-108.03M
Analysts70.59
Price Target14.11 (46.22%)
Short Float %7.85%
Short Ratio5.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.26%
Min EPS beat(2)40.97%
Max EPS beat(2)53.54%
EPS beat(4)4
Avg EPS beat(4)56.53%
Min EPS beat(4)31.6%
Max EPS beat(4)100%
EPS beat(8)8
Avg EPS beat(8)186.32%
EPS beat(12)12
Avg EPS beat(12)158.94%
EPS beat(16)16
Avg EPS beat(16)128.09%
Revenue beat(2)2
Avg Revenue beat(2)0.65%
Min Revenue beat(2)0.13%
Max Revenue beat(2)1.18%
Revenue beat(4)2
Avg Revenue beat(4)-0.78%
Min Revenue beat(4)-2.68%
Max Revenue beat(4)1.18%
Revenue beat(8)4
Avg Revenue beat(8)-0.18%
Revenue beat(12)8
Avg Revenue beat(12)1.59%
Revenue beat(16)11
Avg Revenue beat(16)1.85%
PT rev (1m)1.67%
PT rev (3m)10.66%
EPS NQ rev (1m)2.49%
EPS NQ rev (3m)3.37%
EPS NY rev (1m)-2.12%
EPS NY rev (3m)-0.77%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)-0.06%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.14%
Valuation
Industry RankSector Rank
PE 80.42
Fwd PE 59.5
P/S 1.72
P/FCF N/A
P/OCF 238.74
P/B 1.49
P/tB 48.6
EV/EBITDA N/A
EPS(TTM)0.12
EY1.24%
EPS(NY)0.16
Fwd EY1.68%
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)0.04
OCFY0.42%
SpS5.62
BVpS6.47
TBVpS0.2
PEG (NY)2.29
PEG (5Y)N/A
Graham Number4.18
Profitability
Industry RankSector Rank
ROA -7.94%
ROE -12.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.21%
FCFM N/A
ROA(3y)-5.99%
ROA(5y)-5.34%
ROE(3y)-10.33%
ROE(5y)-9.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.44%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.82%
Cap/Sales 3.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.26
Quick Ratio 3.94
Altman-Z 1.56
F-Score4
WACC6.96%
ROIC/WACCN/A
Cap/Depr(3y)45.34%
Cap/Depr(5y)60.15%
Cap/Sales(3y)4.93%
Cap/Sales(5y)6.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5Y-3.04%
EPS Q2Q%50%
EPS Next Y35.15%
EPS Next 2Y72.06%
EPS Next 3Y62.52%
EPS Next 5Y49.25%
Revenue 1Y (TTM)10.11%
Revenue growth 3Y12.58%
Revenue growth 5Y10.35%
Sales Q2Q%10.56%
Revenue Next Year9.75%
Revenue Next 2Y9.5%
Revenue Next 3Y9.84%
Revenue Next 5Y9.72%
EBIT growth 1Y-3.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year149.96%
EBIT Next 3Y42.58%
EBIT Next 5Y34.35%
FCF growth 1Y36.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.53%
OCF growth 3YN/A
OCF growth 5Y29.07%

NEOGENOMICS INC / NEO FAQ

What is the fundamental rating for NEO stock?

ChartMill assigns a fundamental rating of 4 / 10 to NEO.


What is the valuation status for NEO stock?

ChartMill assigns a valuation rating of 1 / 10 to NEOGENOMICS INC (NEO). This can be considered as Overvalued.


How profitable is NEOGENOMICS INC (NEO) stock?

NEOGENOMICS INC (NEO) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for NEO stock?

The Earnings per Share (EPS) of NEOGENOMICS INC (NEO) is expected to grow by 35.15% in the next year.